Highest-materiality recent filing
Century Therapeutics CSO Chad Cowan moves to part-time with reduced salary
Chad Cowan continues as CSO on part-time basis; salary cut to $296,150 annually.
Century Therapeutics shareholders approve increase in authorized common stock to 450M shares
Stockholders approved amendment to increase authorized common stock from 300M to 450M shares; effective June 12, 2026.
CNTY-813 maintained glucose control for >8 months in diabetic mouse models without immunosuppression.
Net loss of $21.6M for Q1 2026 vs net income of $76.6M in Q1 2025; R&D $17.1M, G&A $6.6M.
Century Therapeutics updates ATM program; $131.6M remaining under $150M facility
New prospectus supplement filed March 26, 2026 for existing ATM program under effective shelf.
Century Therapeutics FY2025 net loss $9.6M; $135M placement extends cash into Q1 2029
Net loss of $9.6M improved from $126.6M in 2024; collaboration revenue from BMS rose to $109.2M (from $6.6M).
Century Therapeutics regains Nasdaq bid price compliance; reverse split not needed
Nasdaq notified Century on Jan 22, 2026 that it regained compliance with minimum $1.00 bid price rule.
Filed updated slide presentation under Item 7.01 used in investor meetings, dated January 12, 2026.
Century Therapeutics raises $135M in oversubscribed private placement to fund CNTY-813 T1D program
Gross proceeds ~$135M; 117.4M shares/pre-funded warrants + 58.7M warrants at $1.15 per unit.
Director Carlo Rizzuto resigns from Century Therapeutics board effective Dec 18, 2025
Carlo Rizzuto, Ph.D. resigned from the board of directors effective December 18, 2025.
Century Therapeutics furnishes updated investor presentation on Dec 12, 2025
Updated slide presentation attached as Exhibit 99.1, dated December 2025.
Century Therapeutics appoints Dr. Murphy and Dr. Lee to Board, expanding from six to eight members
Board expanded from six to eight directors; Dr. Murphy (Class III, term to 2027) and Dr. Lee (Class II, term to 2026) appointed.
Century Therapeutics announces CNTY-813 T1D program; Q3 net loss $34.4M, cash $132.7M
CNTY-813 is iPSC-derived beta islet therapy for T1D; preclinical data show reversal of diabetes in mouse models.
Received 180-day extension until Feb 23, 2026 to meet $1.00 minimum bid price rule after Aug 26 initial deadline.
Century Therapeutics Q2 net loss $32.5M; cash runway into Q4 2027; CEO named Board Chair
Net loss of $32.5M for Q2 2025 (vs. $31.2M in Q2 2024); cash & equivalents $158.5M as of June 30.
Century Therapeutics cuts 51% of workforce; CFO and CDO to depart
Board approved reduction in force of ~51% of employees; expects $3.7M in severance costs.
Daphne Quimi elected with 52,593,454 votes for; Carlo Rizzuto elected with 51,373,990 votes for.
Century Therapeutics Q1 net income $76.6M on BMS termination revenue; CNTY-101 dosing started
Net income of $76.6M vs $28.1M loss in Q1 2024, driven by $109.2M collaboration revenue from BMS deal termination.
Century Therapeutics FY2024 net loss $126.6M; discontinues ELiPSE-1, focuses on CNTY-308
Net loss $126.6M for FY2024 ($136.7M in 2023); cash $220.1M, runway into Q4 2026.
Century Therapeutics receives Nasdaq bid price deficiency notice; 180 days to regain compliance
Nasdaq notified Century Therapeutics on Feb 26, 2025 that its stock closed below $1.00 for 31 consecutive business days.
Century Therapeutics reports preliminary Q4 2024 cash of ~$220M
As of Dec 31, 2024, cash, cash equivalents and investments approx $220M.
BMS terminates collaboration with Century Therapeutics without cause; effective March 12, 2025
BMS notified Century on Dec 12, 2024 of termination of the 2022 Research, Collaboration and License Agreement.
Net loss $31.2M in Q3 2024; cash $244.7M; expects cash to support operations into H2 2026.
Century Therapeutics appoints Morgan Conn, Ph.D. as CFO effective Oct 14, 2024
Morgan Conn, formerly CBO of Pharvaris, appointed CFO; effective October 14, 2024.
Century Therapeutics Q2 2024: Cash $269.6M, initiates Phase 1 SLE trial, advances CNTY-101
Initiated Phase 1 CALiPSO-1 trial of CNTY-101 in Systemic Lupus Erythematosus, with protocol amended to include Lupus Nephritis cohort; expects initial data by year-end 2024.
CNTY-101 ELiPSE-1 Phase 1 data: 30% CRR, 40% ORR overall; 40% CRR, 60% ORR at highest dose levels in Schedule A.
Century Therapeutics files financials of acquired Clade; Clade had $38.6M net loss in 2023
Clade's audited FY2023 net loss $38.6M, accumulated deficit $51.8M as of Dec 31, 2023.
Kimberly Blackwell, Joseph Jimenez, Brent Pfeiffenberger elected as Class III directors with >59M votes for each.
Century Therapeutics reports Phase 1 ELiPSE-1 data: 30% CRR, 40% ORR in R/R NHL; no DLTs
As of March 27, 2024, 12 patients evaluable for safety; no DLTs or GvHD observed; most cycles outpatient.
Century Therapeutics Q1 2024 net loss $28.1M; expands autoimmune plans
Net loss of $28.1M for Q1 2024 vs $31.3M in Q1 2023; R&D expenses $23.4M, down from $24.9M.
Century Therapeutics updates pipeline; CNTY-101 shows durable responses, no allo-rejection in Ph1
CNTY-101 (CD19 iNK) in Ph1 ELiPSE-1 shows favorable safety, 2 CRs including 6-month durable CR, no allo-rejection.
Century Therapeutics raises $60M and acquires Clade Therapeutics to expand autoimmune pipeline
Private placement of ~15.87M shares at $3.78 (April 10 close) led by Bain Capital Life Sciences; expected close April 15, 2024.
Century Therapeutics presents novel iPSC-derived cell therapy preclinical data at AACR 2024
CD19xCD22 bispecific CAR showed cytotoxicity against CD19/CD22 tumor cells in vitro and in xenograft models.
Century Therapeutics reports FY2023 net loss $136.7M; cash $261.8M, runway into 2026
Net loss $136.7M in 2023 vs $131.0M in 2022; R&D expenses $92.7M, down from $97.2M.
Century Therapeutics CFO Michael Diem resigns; Douglas Carr named interim CFO
CFO Michael C. Diem resigned effective Feb 2, 2024; company has initiated a search for a permanent replacement.
Century Therapeutics presents initial CNTY-101 data supporting multi-dosing strategy at ASH
Single-patient case study at Dose Level 1 (100 million cells) showed six-month durable complete response in high-risk R/R B-cell lymphoma
FDA clears IND for Century's CNTY-101 in systemic lupus erythematosus
FDA notified Century that Phase 1 trial of CNTY-101 may proceed in moderate-to-severe SLE patients who failed ≥2 immunosuppressive therapies.
Century Therapeutics appoints Brent Pfeiffenberger as President and CEO, effective Dec 4, 2023
Brent Pfeiffenberger appointed CEO and to Board; Gregory Russotti transitions to Chief Technology and Manufacturing Officer.
Century Therapeutics Q3 net loss $32.7M, appoints Brent Pfeiffenberger CEO
Brent Pfeiffenberger appointed CEO effective Dec 4, 2023; Greg Russotti becomes Chief Technology and Manufacturing Officer.
Cash, cash equivalents and investments of $301M at Q2 2023; runway extends into 2026.
Century Therapeutics Q2 net loss $33.3M; cash $301M; CNTY-101 data expected by year end
Net loss of $33.3M for Q2 2023 vs $31.0M in Q2 2022; net cash used in operations $48.5M in H1 2023.
Century Therapeutics elects three Class II directors and ratifies Ernst & Young at annual meeting
Elected Class II directors: Cynthia Butitta, Timothy Walbert, Alessandro Riva; each term until 2026.
Century Therapeutics Q1 net loss $31.3M; cash $334.8M; CNTY-101 data expected by year end
Q1 net loss $31.3M vs $37.5M prior year; R&D expenses $24.9M, G&A $8.9M.
Century Therapeutics details CEO Flores' severance and CFO Diem's compensation
Flores receives 12 months base salary severance, COBRA reimbursement, and extended option exercise to 3 years.
Century Therapeutics repays $10.6M Hercules loan, terminates Loan Agreement
Prepaid $10.6M aggregate payoff including $100K prepayment charge and $395K exit fee.
Osvaldo Flores stepped down as President, CEO, and Board member effective April 11, 2023; no disagreement with the company.
Filing under Item 7.01 includes an investor presentation dated March 20, 2023, used in meetings with investors.
Century Therapeutics FY2022 net loss $130.9M; cash runway extended into 2026
Net loss of $130.9M for FY2022 vs $95.8M in FY2021; R&D expenses $97.2M (up 29%).
Century Therapeutics discloses ~$3M uninsured at SVB; less than 1% of total cash
Company has ~$3 million in cash/cash equivalents/restricted cash with SVB in excess of FDIC insurance limit.
Century Therapeutics restructures pipeline, cuts headcount 25% to extend cash runway into 2026
De-prioritizes CNTY-103 (glioblastoma) and discovery program; focuses on CNTY-101, CNTY-102, CNTY-107.
On September 26, 2024, the Century Therapeutics, Inc. (the “Company”) announced the appointment of Morgan Conn, Ph.D. to serve as the Company’s Chief Financial Officer, effective October 14, 2024 (the “Effective Date”).
Following the effectiveness of Dr. Diem’s resignation and until a new Chief Financial Officer is appointed, Douglas Carr, the Company’s Senior Vice President, Finance and Operations, will serve as interim Principal Financial Officer.
On January 15, 2024, Michael C. Diem, M.D. notified Century Therapeutics, Inc. (the “Company”) of his decision to resign as Chief Financial Officer of the Company, effective as of February 2, 2024.
appointed Brent Pfeiffenberger to serve as the Company’s President and Chief Executive Officer, effective December 4, 2023
Dr. Pfeiffenberger was appointed to serve as a member of the Board
Dr. Russotti will serve as the Company’s Chief Technology and Manufacturing Officer.
Osvaldo Flores, Ph.D. stepped down as the President and Chief Executive Officer of the Company and as a member of the Board of Directors of the Company (the “Board”) effective April 11, 2023.
On April 11, 2023, the Board promoted Dr. Michael Diem to Chief Financial Officer.
On April 11, 2023, the Board appointed Gregory Russotti as Interim President and Chief Executive Officer.
On April 11, 2023, the Board promoted Michael Diem to Chief Financial Officer.
Osvaldo Flores, Ph.D. stepped down as the President and Chief Executive Officer of Century Therapeutics, Inc. (the “Company”) and as a member of the Board of Directors of the Company (the “Board”) effective April 11, 2023.
Eli Casdin tendered his resignation as a member of the board of directors (the “ Board ”) of Century Therapeutics, Inc.
Max materiality 0.85 · Median 0.60 · Most common event other_material